Key Highlights

  • Moleculin Biotech (NASDAQ:MBRX) was trading down 10.63% at USD 7.20 in pre-market on Friday, November 13, 2026, with no company announcement dated November 11 to November 13 found.
  • Interim data announced on November 4, 2026 from the first 45 patients showed complete remission rates of 43% and 36% in the two annamycin arms, against 12% for placebo.
  • The company reported no signs of cardiotoxicity through the data cutoff, and an independent monitoring committee recommended that the study continue without changes.
  • A poster on the MIRACLE trial is set for the American Society of Hematology meeting in New Orleans, which runs from December 12 to December 15, 2026.

Pullback Follows the November 4 Interim Readout

Moleculin Biotech was quoted at USD 7.20 in pre-market, down 10.63%. No new release, filing or analyst action in the November 11 to November 13, 2026 window was found, so the move is best read against the November 4 interim analysis of the MIRACLE (MB-108) Phase 2/3 trial. The company develops annamycin, an anthracycline designed to avoid multidrug resistance and the heart toxicity linked to older drugs, for relapsed or refractory acute myeloid leukemia. A move after a trial readout is often profit-taking, and the pre-market quote is the figure of record only for this session. The stock is quoted at USD 7.20 and the previous close implied by the screener is about USD 8.06, calculated.

What the MIRACLE Interim Data Showed

The first prespecified interim analysis covered 45 randomized patients with relapsed or refractory AML receiving annamycin with cytarabine. Complete remission rates were 43% and 36% in the two annamycin arms against 12% in the placebo arm. The company said it saw no signs, symptoms or echocardiographic findings suggesting cardiotoxicity through the cutoff, and the Data Monitoring Committee advised continuing without amendment. The abstract, titled as a pivotal Phase 2/3 study of naxtarubicin, another name for annamycin, was accepted as a poster at the 68th ASH Annual Meeting. Interim data from a small group can change as enrolment grows. The company describes itself as a Phase 3 clinical-stage firm, and its pipeline also includes WP1066 and WP1122.

Dilution Overhang From the July Offering

The financing record is a risk. On July 31, 2026 the company priced a public offering of 12,376,667 shares, or pre-funded warrants, at USD 0.75 with common warrants for up to 37,130,001 shares exercisable at USD 0.75, for about USD 9.3 million of gross proceeds. Those terms may not reflect any later share consolidation, and none was verified here, so they cannot be compared with the USD 7.20 quote. If the Warrant terms are unchanged, exercises could add supply. A resale registration for 18.2 million shares by holders was also reported, with the date unconfirmed. Biotech holders often sell into strength once a readout is in the market, and a drop of this size is not unusual.

Where Things Stand

The decline most likely reflects trading after the November 4 data, not new news. Moleculin Biotech (NASDAQ:MBRX) was down 10.63% at USD 7.20 in pre-market, and no announcement explains the day's move. The data were positive on remission and safety, but they come from 45 patients, and warrants and resale registrations from earlier financings add potential supply. Next markers are further enrolment in MIRACLE and the ASH poster in December 2026. Pre-market quotes can reverse once regular trading opens. Investors will watch whether the full study reproduces the interim gap between annamycin and placebo.